
Daewoong Pharmaceutical's gastroesophageal reflux disease treatment 'Pexclue' demonstrated a higher complete healing rate than existing treatments in a clinical trial for gastric ulcers that developed after endoscopic procedures. The time required for ulcers to heal completely was also approximately 7 days shorter, securing clinical evidence for its use in treating post-endoscopy gastric ulcers.
On the 20th, Daewoong Pharmaceutical announced that it confirmed these results in a clinical trial comparing the therapeutic effects of Pexclue (active ingredient: pexoprazan) and esomeprazole on iatrogenic gastric ulcers occurring after endoscopic submucosal dissection (ESD).
The study was conducted from June 2024 to October 2025 in a multi-center, double-blind, randomized controlled manner involving 107 patients. Researchers administered either Pexclue 40 mg or esomeprazole 40 mg once daily for eight weeks and evaluated ulcer shrinkage rates and complete healing rates at the four-week and eight-week marks.
As a result, the complete healing rate of gastric ulcers in the Pexclue group at the eight-week mark was 90.2%, which was 15.2 percentage points higher than that of the esomeprazole group (75.0%). The difference between the two groups was statistically significant (p=0.040).
The estimated time to complete healing was also approximately 7 days shorter in the Pexclue group at 40.31 days compared to the esomeprazole group (47.22 days) (p=0.0449). The ulcer shrinkage rate was also statistically significantly higher in the Pexclue group at both the four-week and eight-week time points. Positive results regarding healing time were also observed in the patient group with an ulcer area of 800 square millimeters or more.
ESD is a procedure that removes tumors occurring in the gastric mucosa using endoscopy. During the procedure, iatrogenic gastric ulcers form at the resection site, and if they do not heal sufficiently, the risk of complications can increase, making appropriate acid suppression therapy necessary.
Pexclue is a potassium-competitive acid blocker (P-CAB) class treatment developed by Daewoong Pharmaceutical. Esomeprazole, used as a comparator in this study, is a proton pump inhibitor (PPI) class drug, and the two medications differ in their mechanism of suppressing gastric acid secretion.
The results of this study were presented as posters at SIDDS 2026 and UEG 2026, domestic and international academic conferences related to digestive diseases. The research paper received acceptance for publication on September 28 from the international academic journal 'World Journal of Gastroenterology' and is scheduled for formal publication in January 2027.
Professor Heo Cheol-woong of Yongin Severance Hospital, the principal investigator of the study, explained, "In this study, Pexclue 40 mg completely healed post-ESD gastric ulcers at a higher rate and more quickly than esomeprazole, with safety at a similar level." He added, "In particular, the fact that the time to complete healing was shortened by approximately 7 days is a result confirming the rapid and potent acid secretion suppression effect of P-CABs in treating iatrogenic ulcers after ESD."
Park Hyeong-cheol, Head of the ETC Marketing Division at Daewoong Pharmaceutical, stated, "This study is significant in that it confirmed Pexclue can heal ulcers in more patients and more quickly compared to existing PPI treatments for iatrogenic gastric ulcers that may occur after endoscopic procedures." He added, "Going forward, we will strive to provide the optimal treatment environment tailored to patients' conditions and medication environments through various clinical studies and the expansion of treatment options."